Direct Answer
Syn-Ake is a cosmetic dipeptide (a synthetic waglerin-1 mimetic) marketed for expression lines; independent peptide-specific evidence is limited.
Summary Table
Evidence Level
Preclinical
AI Summary
Syn-Ake (INCI Dipeptide Diaminobutyroyl Benzylamide Diacetate) is a synthetic cosmetic dipeptide designed to mimic waglerin-1, a component of temple viper venom, and is marketed in the "neuro-cosmetic" category for expression lines. The evidence base is preclinical and limited: available studies include in silico and in vitro anti-aging assessments and multi-ingredient clinical cosmetic studies, rather than controlled trials isolating the peptide. It is a cosmetic ingredient, not an approved medicine, and marketed effects are not established for the peptide alone.
Key Information
Classification
Key Takeaways
- Syn-Ake is a cosmetic dipeptide (waglerin-1 mimetic) marketed for expression lines
- Evidence is in silico, in vitro, or from multi-ingredient formulations
- It is a cosmetic ingredient, not an approved medicine
Scientific Overview
In Plain English
Syn-Ake is a cosmetic peptide designed to imitate a component of snake venom (waglerin-1). It is marketed to relax expression lines. The available research includes computer modelling, lab tests, and studies of full cosmetic formulas rather than the peptide by itself. It is a cosmetic ingredient, not a medicine.
Scientific Details
Syn-Ake (Dipeptide Diaminobutyroyl Benzylamide Diacetate) is a synthetic dipeptide marketed as a waglerin-1 mimetic proposed to antagonize the muscle nicotinic acetylcholine receptor, reducing expression-line appearance. Available literature includes in silico and in vitro anti-aging assessments and clinical studies of multi-ingredient serums containing the peptide; controlled trials isolating the peptide are limited.
How It Works
Syn-Ake is described as a waglerin-1 mimetic proposed to antagonize the muscle-type nicotinic acetylcholine receptor, an activity marketed as relaxing expression lines. This proposed mechanism is characterized in silico and in vitro and is not established by controlled human efficacy studies isolating the peptide.
Mechanism of Action
Proposed nicotinic acetylcholine receptor antagonism
cell
Marketed as a waglerin-1 mimetic proposed to antagonize the muscle nicotinic acetylcholine receptor; characterized in silico and in vitro, not established in controlled human efficacy studies isolating the peptide.
Evidence Level
Human Evidence
Human data come mainly from studies of multi-ingredient cosmetic serums containing the peptide, which do not isolate its individual effect.
Cell Evidence
In silico and in vitro studies describe proposed anti-aging activity.
Limitations
Controlled trials isolating the peptide are limited; marketed effects are not established for the peptide alone.
Why This Grade
Graded preclinical: evidence is in silico, in vitro, or from multi-ingredient formulations, without controlled human trials isolating the peptide.
Frequently Asked Questions
How is Syn-Ake proposed to work?
Syn-Ake is marketed as a waglerin-1 mimetic proposed to antagonize the muscle nicotinic acetylcholine receptor. That mechanism is characterized in silico and in vitro and is not established in controlled human efficacy studies that isolate the peptide.
How strong is the evidence for Syn-Ake?
It is preclinical. Syn-Ake’s proposed activity is characterized in silico and in vitro; controlled trials isolating the peptide are limited, and the human data come from studies of multi-ingredient serums that do not isolate its effect — so marketed effects are not established for the peptide alone. The one clinical source is a manufacturer study (L’Oréal) of a five-active serum.
Does Syn-Ake work like Botox for expression lines?
No. Syn-Ake is a cosmetic dipeptide, not a medicine and not a botulinum-toxin (Botox) product, and it is not comparable to an injectable neurotoxin. It is a synthetic waglerin-1 mimetic proposed to antagonize the muscle nicotinic acetylcholine receptor, but that mechanism is characterized only in silico (computer modeling) and in vitro (in the lab) — not in controlled human studies that isolate the peptide. The human data come from multi-ingredient cosmetic serums containing it, so the marketed anti-aging effect cannot be attributed to the peptide alone.
References
- Anti-aging activity of Syn-Ake peptide by in silico approaches and in vitro tests. Journal of Biomolecular Structure & Dynamics. (Academic (Yildiz Technical University / Istanbul University); no competing-interests statement in the record — not asserted independent.)Cell / In Vitrodoi:10.1080/07391102.2023.2223681 →
- The effect of a serum containing acetyl hexapeptide-8, dipeptide diaminobutyroyl benzylamide diacetate and gluconolactone on skin biomarkers, wrinkles and skin texture: Ex vivo and clinical studies. International Journal of Cosmetic Science. (Authored by L'Oréal Research & Innovation employees evaluating a L'Oréal serum containing the peptide — manufacturer study.)Ex-vivo plus clinical evaluation (n=50; n=42) of a 5-active serum (acetyl hexapeptide-8, this peptide, gluconolactone, niacinamide, laminaria extract). Tests the combination; does not isolate Syn-Ake's individual effect.Human Studydoi:10.1111/ics.70087 →
Alternative Names
- Dipeptide Diaminobutyroyl Benzylamide Diacetate
- Waglerin-1 mimetic
Risks & Safety
- Not a medicine; used as a cosmetic ingredient with the usual patch-test considerations
- Independent evidence specific to the peptide is limited; marketed anti-aging effects are not established
- Clinical data involve multi-ingredient formulations, so effects cannot be attributed to the peptide alone
Claim Boundaries
ION BLUE is an educational research aggregator. This content summarizes published scientific literature. It is not medically reviewed, is not medical advice, and is not a recommendation to use any substance. Consult a licensed healthcare provider. This entry summarizes limited cosmetic-ingredient research and is not an assertion that Syn-Ake produces any particular result.
This page summarizes published research and is for informational purposes only; it is not medical advice.